Depo-Provera Settlement 2026: What the New Global Agreement Means for Your Claim

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 135 Aug 2026N.D. Fla. CMO 1410 Aug 2026

Last Updated: September 24, 2026 | Published by: Mason Arnao | Primary Sources: N.D. Fla. Pretrial Order No. 30A and Case Management Orders No. 12, 13 and 14, the official MDL 3140 court page, the JPML pending-actions report of September 1, 2026, and the U.S. Depo-Provera CI label.

A global Depo-Provera settlement agreement was announced on June 15, 2026 — the most significant development in this litigation since it began. If you or a loved one used Depo-Provera injectable birth control and developed a meningioma brain tumor, this news may directly affect your right to compensation. Here is everything confirmed so far about the agreement, and what you need to do right now to protect your claim.

What Is the Depo-Provera Settlement Agreement?

On June 15, 2026, U.S. District Judge M. Casey Rodgers issued Pretrial Order No. 30A, which refers to a “global agreement” between Plaintiffs’ Lead Counsel and defendants Pfizer Inc., Pharmacia LLC and Pharmacia & Upjohn Co. LLC under which MDL plaintiffs who meet the agreed eligibility criteria will have an opportunity to resolve their claims. Christopher Seeger serves as Plaintiffs’ Lead Counsel under Pretrial Order No. 31. As of the JPML’s September 1, 2026 report, 6,403 actions were pending in MDL No. 3140.

SourceN.D. Fla. PTO 30A15 Jun 2026N.D. Fla. PTO 3120 Mar 2026JPML MDL report1 Sep 2026

A Depo-Provera settlement, in plain terms, is a negotiated resolution between Pfizer and claimants who allege that long-term use of the injectable birth control caused them to develop meningiomas — typically benign but potentially serious tumors of the membranes surrounding the brain or spinal cord. The goal of a global agreement is to resolve thousands of claims without requiring individual jury trials.

Confirmed facts as of September 24, 2026:

• June 15, 2026 — Pretrial Order No. 30A referred to the parties’ global agreement, noted that it will not resolve all cases in the MDL, and continued the Rule 702 hearing from June 24–25 to July 27, 2026.
• June 15, 2026 — the court vacated the Pilot-case schedule and cancelled the December 2026 trial, because the original Pilot plaintiffs are eligible to participate in the settlement.
• July 21, 2026 — the parties signed a confidential Master Settlement Agreement; they estimate roughly 80% of MDL plaintiffs are eligible.
• August 10, 2026 — Case Management Order No. 14 set November 30, 2026 as the deadline for claimants to register for the Settlement Program.
• September 18, 2026 — the date the court set for the Rule 702 hearing; its rulings apply to cases outside the settlement.

SourceN.D. Fla. PTO 30A15 Jun 2026N.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 1410 Aug 2026

Not public: The payout amounts, payout tiers and full eligibility criteria are in the confidential Master Settlement Agreement and have not been released. No specific figure you see elsewhere should be treated as an official Pfizer offer.

SourceN.D. Fla. CMO 1227 Jul 2026

What Is the Depo-Provera Lawsuit About?

Depo-Provera (medroxyprogesterone acetate) is an injectable contraceptive made by Pfizer used by millions of women for decades. Plaintiffs in the Depo-Provera lawsuit allege that long-term use significantly increases the risk of meningioma — a brain or spinal tumor that can require major surgery, radiation, and cause lasting neurological harm.

The scientific case gained momentum from two peer-reviewed studies. A 2024 national case-control study in The BMJ found that prolonged use (one year or more) of injectable medroxyprogesterone acetate was associated with about 5.6 times the odds of intracranial meningioma requiring surgery (odds ratio 5.55). A 2025 U.S. study in JAMA Neurology found that users of depot medroxyprogesterone acetate had 2.43 times the risk of a meningioma diagnosis compared with matched controls; the authors reported a number needed to harm of 1,152, so the absolute risk remains low.

SourceBMJ 2024;384:e07807827 Mar 2024JAMA Neurology 2025Nov 2025

In December 2025, the U.S. prescribing information for Depo-Provera CI was updated with a meningioma warning (section 5.4), which tells prescribers to monitor patients for signs and symptoms of meningioma and to discontinue the drug if one is diagnosed. MDL No. 3140, presided over by Judge Rodgers in the Northern District of Florida since the JPML centralized it on February 7, 2025, had 6,403 pending actions as of September 1, 2026.

SourceDepo-Provera CI labelRev. 12/2025N.D. Fla. MDL 3140JPML MDL report1 Sep 2026

What We Know About Depo-Provera Settlement Value So Far

Because the settlement terms are confidential, any specific dollar amount circulating online is speculative. Here is what the record shows:

Confirmed: A global Depo-Provera settlement agreement exists, and the Master Settlement Agreement signed on July 21, 2026 is governed by a confidentiality agreement. No official payout figures have been announced by Pfizer or the court.

What is not public: No total, no per-claim allocation and no payout matrix have been made public, so no individual payout figure can be stated. Ranges circulated by plaintiff firms are estimates, not reported settlement terms.

SourceN.D. Fla. CMO 1227 Jul 2026

For what has and has not been disclosed about amounts, see our Depo-Provera settlement amounts guide.

Do You Qualify for the Depo-Provera Settlement?

The settlement’s full eligibility criteria are in the confidential Master Settlement Agreement and have not been published. Court orders confirm that some plaintiffs are ineligible because of when they filed, or because of when they were diagnosed relative to their last use of medroxyprogesterone acetate. Attorneys evaluating claims generally look for these factors:

• Meningioma diagnosis — A confirmed medical diagnosis of meningioma (brain or spinal cord) is the central injury alleged in this litigation.
• History of Depo-Provera injections — Documented use of the injectable birth control, often for 12 months or more, though shorter-term use may still be evaluated.
• Medical and pharmacy records — Records linking Depo-Provera use and meningioma diagnosis are typically required to support a claim.
• Deadlines — The deadline for claimants to register for the Settlement Program is November 30, 2026, and state statutes of limitations continue to run.
• Wrongful death claims — Surviving family members may qualify if a loved one died from a Depo-Provera-linked meningioma.

SourceN.D. Fla. CMO 1410 Aug 2026

Judge Rodgers has made clear the global agreement will not cover every MDL claimant. Speaking with an attorney now gives you the best chance to understand exactly where your claim stands — and whether it falls inside or outside the settlement framework. You may also qualify for other active mass tort lawsuits TortAdvisor tracks nationwide.

SourceN.D. Fla. PTO 30A15 Jun 2026

How Much Could Your Depo-Provera Settlement Be Worth?

The value of an individual claim in this Depo-Provera settlement depends on a combination of medical, financial, and legal factors. No official tiers have been published, but attorneys evaluating cases weigh several key elements. To explore those factors, see our Depo-Provera settlement calculator.

Tumor severity is one of the strongest value drivers. A large meningioma requiring emergency surgery, causing lasting cognitive or neurological impairment, or recurring after initial treatment is likely to command substantially higher compensation. The scope of medical treatment — surgery, radiation therapy, hospitalization, and specialist follow-up — directly affects both economic damages and the overall strength of a claim.

Lost income and reduced earning capacity are also major factors, particularly for claimants in their peak working years at the time of diagnosis. Neurological effects from meningioma and its treatment can permanently limit a person’s ability to work — courts and settlement administrators weigh this heavily in comparable mass tort cases. Duration of Depo-Provera use matters too: the 2024 BMJ study tied the excess risk to prolonged use of one year or more, which can strengthen causation arguments.

SourceBMJ 2024;384:e07807827 Mar 2024

What Happens Next in the Depo-Provera MDL?

The settlement is now in administration. The parties signed the Master Settlement Agreement on July 21, 2026, and on August 5, 2026 the court appointed BrownGreer PLC as Settlement Administrator under CMO No. 13. Because the agreement is private, its payout tiers and eligibility criteria have not been published. The deadline for claimants to register is November 30, 2026 (CMO No. 14), and payments are represented as beginning to roll out by Q1 2027.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 135 Aug 2026N.D. Fla. CMO 1410 Aug 2026

Rule 702 / Daubert track: Pretrial Order No. 30A moved the general-causation hearing from June 24–25 to July 27, 2026, and the court later set it for September 18, 2026, following that day’s case management conference. No ruling had been posted on the court’s MDL page as of September 24, 2026. The rulings will not affect plaintiffs who are eligible for the settlement and participate; they matter for claims outside it, since the parties estimated roughly 80% — not all — of MDL plaintiffs would be eligible.

SourceN.D. Fla. PTO 30A15 Jun 2026N.D. Fla. CMO 1227 Jul 2026

Claimants outside the settlement: Pretrial Order No. 30A states that the global agreement will not resolve all cases in the MDL. Plaintiffs who do not participate remain in active litigation and must meet case-specific discovery deadlines under Case Management Order No. 14; the court approved three substitute Pilot cases on July 27, 2026 after the original Pilot plaintiffs became eligible to participate in the settlement.

SourceN.D. Fla. PTO 30A15 Jun 2026N.D. Fla. CMO 1410 Aug 2026N.D. Fla. CMO 1227 Jul 2026

Act before the registration deadline: The deadline for claimants to register for the Settlement Program is November 30, 2026, and statutes of limitations continue to run. If you have a meningioma diagnosis linked to Depo-Provera use, contacting an attorney now is the single most important step you can take.

SourceN.D. Fla. CMO 1410 Aug 2026

Frequently Asked Questions

Was a Depo-Provera settlement announced in 2026?

Yes. On June 15, 2026, plaintiffs’ leadership counsel announced a settlement with Pfizer of a majority of the claims in MDL No. 3140 and New York state court; Pretrial Order No. 30A, entered that day, refers to the parties’ “global agreement.” A confidential Master Settlement Agreement was signed on July 21, 2026. No amounts have been disclosed, and the deadline for claimants to register for the Settlement Program is November 30, 2026.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. PTO 30A15 Jun 2026N.D. Fla. CMO 1410 Aug 2026

How much will Depo-Provera settlement claims pay?

No payout amounts have been announced. The settlement is governed by a confidentiality agreement, and no total fund, per-claim allocation or payout matrix has been made public, so no individual payout figure can be stated.

SourceN.D. Fla. CMO 1227 Jul 2026

Who qualifies for the Depo-Provera settlement?

Eligibility is set by the confidential Master Settlement Agreement; the parties estimate roughly 80% of MDL plaintiffs are eligible. Court orders confirm that some plaintiffs are ineligible because of when they filed their case, or because of when their meningioma was diagnosed relative to their last use of medroxyprogesterone acetate. Family members of people who died may be able to bring wrongful death claims under state law.

SourceN.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 1410 Aug 2026

Does the global agreement cover all MDL claimants?

No. Judge Rodgers noted in Pretrial Order No. 30A that the global Depo-Provera settlement will not resolve all cases in MDL-3140. Some claimants will remain in active litigation. The parties estimated that roughly 80% of MDL plaintiffs would be eligible under the private Master Settlement Agreement signed on July 21, 2026, which is the parties’ own estimate rather than a determination about any individual case. The agreement’s complete eligibility criteria are confidential and have not been published, so whether a particular claim falls inside or outside it is a question for an attorney reviewing that claim. Plaintiffs who do not participate must meet case-specific discovery deadlines under Case Management Order No. 14 (August 10, 2026).

SourceN.D. Fla. PTO 30A15 Jun 2026N.D. Fla. CMO 1227 Jul 2026N.D. Fla. CMO 1410 Aug 2026

What is the Daubert hearing, and how does it affect the settlement?

The Rule 702 (Daubert) hearing decides whether plaintiffs’ general-causation experts can testify. It was set for June 24–25, 2026; Pretrial Order No. 30A moved it to July 27, and the court later set it for September 18, 2026. The rulings will not affect plaintiffs who are eligible for the settlement and choose to participate; they apply to cases that are ineligible or opt out. No ruling had been posted on the court’s MDL page as of September 24, 2026.

SourceN.D. Fla. PTO 30A15 Jun 2026N.D. Fla. CMO 1227 Jul 2026

Should I wait before contacting an attorney about my Depo-Provera claim?

No. The deadline for claimants to register for the Settlement Program is November 30, 2026, and statutes of limitations continue to run during the settlement process. Speaking with an attorney now is the best way to protect your claim.

SourceN.D. Fla. CMO 1410 Aug 2026

Related Articles